Application of cyclobenzaprine hydrochloride in preparation of medicine for treating esophageal cancer

The inhibition of JAK1/STAT3/WDHD1 signaling axis by cyclobenzaprine hydrochloride significantly inhibits the proliferation and metastasis of esophageal cancer cells, solving the problems of chemotherapy resistance and side effects of esophageal cancer, providing new treatment options and expanding its clinical indications .

CN118903078APending Publication Date: 2024-11-08川北医学院附属医院
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411217524.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Chemotherapy drugs for esophageal cancer are highly resistant to drugs and have obvious side effects of conventional drugs, resulting in a long development cycle and high failure rate of new drugs, and a lack of effective anti-esophageal cancer drugs.

Method used

Cyclobenzaprine hydrochloride is used as a new anti-esophageal cancer drug. By inhibiting the signal axis of JAK1/STAT3/WDHD1, it significantly inhibits the proliferation and metastasis of esophageal cancer cells, it has been developed into various dosage forms such as tablets and capsules. The effective dose is 30mg/kg.

Benefits of technology

Cyclobenzaprine hydrochloride significantly inhibits the proliferation and metastasis of esophageal cancer cells, provides new treatment options for esophageal cancer, expands its clinical indications, and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903078A_ABST
    Figure CN118903078A_ABST
Patent Text Reader

Abstract

The invention discloses application of cyclobenzaprine hydrochloride in preparation of a medicine for treating esophageal cancer, and relates to the technical field of medicines. Cyclobenzaprine hydrochloride is applied to preparation of the medicine for treating the esophageal cancer, can remarkably inhibit proliferation and metastasis of the esophageal cancer and induce cell cycle arrest, and possibly induces DNA damage reaction by inhibiting a JAK1 / STAT3 / WDHD1 signal axis, so that the anti-cancer effect is achieved, and the clinical application prospect is good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to application of cyclobenzaprine hydrochloride in preparing a medicine for treating esophageal cancer. Background Art

[0002] The morbidity and mortality of esophageal cancer rank 7th and 6th among all malignant tumors, respectively, which seriously threatens human health and brings serious mental and economic pressure to patients and their families. At present, surgery, chemotherapy, radiotherapy, biological therapy, and neoadjuvant therapy are the main treatments for esophageal cancer. However, cancer cells are very susceptible to drug resistance to chemotherapy drugs, and conventional chemotherapy drugs have varying degrees of side effects. Therefore, the development of new anti-esophageal cancer drugs is imminent. The development cycle of new drugs is long, the cost is high, and the failure rate is high. Screening new anti-esophageal cancer drugs from traditional old drugs is an important strategy for its new drug development. At the same time, old drugs have the characteristics of clear efficacy and toxic side effects, and are an important direction for the development of anti-tumor drugs.

[0003] Cyclobenzaprine hydrochloride is a tricyclic antidepressant derivative, commonly used as a muscle relaxant, and has a significant effect on intractable pain of cervical and lumbar origin caused by skeletal muscle spasm. However, there are currently no reports in the literature or patents on the use of cyclobenzaprine hydrochloride in the treatment of esophageal cancer. Summary of the invention

[0004] In order to solve the above technical problems, the purpose of the present invention is to provide an application of cyclobenzaprine hydrochloride in the preparation of a drug for treating esophageal cancer. Cyclobenzaprine hydrochloride can significantly inhibit the proliferation and metastasis of esophageal cancer and induce cell cycle arrest. It may induce DNA damage response by inhibiting the JAK1 / STAT3 / WDHD1 signaling axis, thereby exerting an anti-cancer effect, and has good clinical application prospects.

[0005] The technical solution of the present invention to solve the above technical problem is as follows: provide an application of cyclobenzaprine hydrochloride in the preparation of a drug for treating esophageal cancer.

[0006] Furthermore, the drug dosage form is tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, electuary preparations, pills, pills, suspensions, wine preparations, tinctures or drops.

[0007] Furthermore, the medicament contains at least one pharmaceutically acceptable carrier or excipient.

[0008] Furthermore, animal experiments have shown that the effective dose of cyclobenzaprine hydrochloride is 30 mg / kg.

[0009] Further, cyclobenzaprine hydrochloride, molecular formula C 20 H 21 N·HCl, molecular weight is 311.85, molecular structure is:

[0010]

[0011] The present invention has the following beneficial effects:

[0012] 1. Cyclobenzaprine hydrochloride can significantly inhibit the vitality and proliferation of esophageal cancer cells; it can also significantly inhibit the metastatic ability of esophageal cancer cells, upregulate E-cadherin, and downregulate Vimentin expression; cyclobenzaprine hydrochloride can significantly downregulate WDHD1 gene expression, and interference with WDHD1 can also significantly inhibit the proliferation and metastasis of esophageal cancer cells; in terms of mechanism, cyclobenzaprine hydrochloride can downregulate the JAK1 / STAT3 signaling pathway, thereby downregulating WDHD1 expression; overexpression of STAT3 or WDHD1 can partially restore the inhibitory effect of cyclobenzaprine hydrochloride on the proliferation and metastasis of esophageal cancer cells. Animal experiments confirmed that the tumor volume and weight of subcutaneous transplanted tumors in nude mice treated with cyclobenzaprine hydrochloride (30 mg / kg) were significantly lower than those in the DMSO group, suggesting that it can also exert significant anti-esophageal cancer activity in vivo.

[0013] 2. Cyclobenzaprine hydrochloride can significantly inhibit the proliferation and metastasis of esophageal cancer, and its clinical application prospect for the treatment of esophageal cancer is good; this study not only developed a new clinical use for cyclobenzaprine hydrochloride, but also provided a new option for the drug treatment of esophageal cancer.

[0014] 3. The present invention explores the effects and molecular mechanisms of cyclobenzaprine hydrochloride in treating esophageal cancer, expands the clinical indications of cyclobenzaprine hydrochloride, and provides a new option for the drug treatment of esophageal cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 To investigate the effects of cyclobenzaprine hydrochloride on the proliferation and metastasis of esophageal cancer cells KYSE150 and Eca109;

[0016] Figure 2 To screen and validate the effector molecules of cyclobenzaprine hydrochloride against the proliferation and metastasis of esophageal cancer;

[0017] Figure 3 Cyclobenzaprine hydrochloride inhibits the proliferation and metastasis of KYSE150 and Eca109 cells by regulating the expression of WDHD1;

[0018] Figure 4 To investigate the effect of cyclobenzaprine hydrochloride on the growth of tumor tissue in a nude mouse xenograft model of esophageal cancer. DETAILED DESCRIPTION

[0019] The principles and features of the present invention are described below, and the examples are only used to explain the present invention and are not used to limit the scope of the present invention. If no specific conditions are specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments is not specified, they are all conventional products that can be purchased commercially.

[0020] Example 1 Cell test: Inhibitory effect of cyclobenzaprine hydrochloride on the growth of esophageal cancer cells

[0021] 1) CCK-8 experiment: KYSE150 and Eca109 esophageal cancer cells were revived and passaged; cells in the logarithmic growth phase were digested and seeded in 96-well plates at a number of 3000 cells per well, and cultured in an incubator at 37°C and 5% CO2; after 24 hours, cells were treated with a certain concentration gradient of cyclobenzaprine hydrochloride (0 μM, 5 μM, 10 μM, 15 μM, 20 μM, 25 μM, 30 μM, 35 μM, 40 μM, 45 μM, 50 μM) for 48 hours, and the IC50 was calculated; KYSE150 and Eca1090 cells were treated with 30 μM cyclobenzaprine hydrochloride for 24, 48, 72, 96, and 120 hours, respectively, and after reaching the time point, the cell viability was detected by CCK-8 experiment.

[0022] 2) Plate cloning experiment: KYSE150 and Eca109 cells in the logarithmic growth phase were digested and seeded into 6-well plates at a number of 1000 cells per well, and cultured in an incubator at 37°C and 5% CO2; after about 7-10 days, the size of the cell clones in the 6-well plates was observed, and 30 μM cyclobenzaprine hydrochloride was added to treat the cells; the growth of the clones was observed every 48 hours, and after 7-10 days of drug treatment, the size of the tumor cell clones in the experimental group and the control group was observed; after the difference in the size of the clones was visible to the naked eye, the culture medium was discarded, and the cells were fixed with 4% paraformaldehyde; after 10 minutes, the paraformaldehyde was discarded and air-dried; the cell spheres were stained with crystal violet solution.

[0023] 3) Western Blot experiment: KYSE150 and Eca109 cells in the logarithmic growth phase were digested and plated at 5×10 5 The cells were inoculated into a 6-well plate at a cell volume of 100 μg / well and cultured in an incubator at 37°C and 5% CO2; after 12 hours, the cells were treated with cyclobenzaprine hydrochloride at a final concentration of 30 μM for 48 hours; the cells were collected and centrifuged at 4000 rpm for 5 minutes; the cells were lysed with protein lysis buffer, the protein concentration was measured, and the expression level of the corresponding protein was detected by Western Blot.

[0024] The results are as follows Figure 1As shown. A is the IC50 of cyclobenzaprine hydrochloride in inhibiting the proliferation of KYSE150 and Eca109 cells; B is the effect of cyclobenzaprine hydrochloride on the viability of KYSE150 and Eca109 cells; C is the effect of cyclobenzaprine hydrochloride on the proliferation of KYSE150 and Eca109 cells; D is the effect of cyclobenzaprine hydrochloride on the metastatic ability of KYSE150 and Eca109 cells; E is the effect of cyclobenzaprine hydrochloride on the expression of E-cadherin and Vimentin in KYSE150 and Eca109 cells.

[0025] Depend on Figure 1 It can be seen that the IC50 of cyclobenzaprine hydrochloride in inhibiting the proliferation of KYSE150 and Eca109 cells is 29.76μM and 24.17μM respectively; cyclobenzaprine hydrochloride can significantly inhibit the vitality and proliferation ability of esophageal cancer, inhibit cell metastasis ability, downregulate E-cadherin expression, and upregulate Vimentin expression. These results suggest that cyclobenzaprine hydrochloride can exert anti-cancer activity by inhibiting the proliferation and metastasis ability of esophageal cancer.

[0026] Example 2 Cell experiment: Inhibitory effect of cyclobenzaprine hydrochloride on metastasis of esophageal cancer cells and possible mechanism

[0027] (1) Transwell assay: Digest KYSE150 and Eca109 cells in the logarithmic growth phase, count and adjust the cell density to 2×10 6 / mL; add 600 μL of complete culture medium to the 12-well plate, take out the Transwell chamber and place it in the 12-well plate containing culture medium; add 100 μL of cell suspension to the Transwell chamber, and add 30 μM cyclobenzaprine hydrochloride to treat the cells; 24 hours later, take out the chamber from the 12-well plate, wipe the cells in the chamber with a cotton swab, and then place the chamber in 4% paraformaldehyde to fix the cells; 10 minutes later, take out the Transwell chamber, dry it and then place it in crystal violet solution for staining; 10 minutes later, take out the Transwell chamber, wash off the excess stain, and dry it at room temperature; observe and take pictures under a microscope, and count the number of migrated cells.

[0028] (2) Scratch test: Digest KYSE150 and Eca109 cells in the logarithmic growth phase, count and adjust the cell density to 1×10 7 / mL; Place a Transwell chamber in a 6-well plate and press 5×10 6The cells were seeded in a chamber with a cell amount of 1:1 / mL and cultured in an incubator at 37°C and 5% CO2. After 24 hours, the chamber was removed, 2 mL of serum-free culture medium was added to the 6-well plate, and 30 μM cyclobenzaprine hydrochloride was added. After 24 hours, the cell migration ability was observed. Pictures were taken, and the scratch area was measured using Image J to calculate the healing rate.

[0029] (3) Western Blot experiment: KYSE150 and Eca109 cells in the logarithmic growth phase were digested and 5×10 5 The cells were inoculated into a 6-well plate at a cell volume of 100 μg / well and cultured in an incubator at 37°C and 5% CO2; after 12 hours, the cells were treated with cyclobenzaprine hydrochloride at a final concentration of 30 μM for 48 hours; the cells were collected and centrifuged at 4000 rpm for 5 minutes; the cells were lysed with protein lysis buffer, the protein concentration was measured, and the expression level of the corresponding protein was detected by Western Blot.

[0030] The results are as follows Figure 2 As shown in the figure. A is the proteomics screening of effector molecules in esophageal cancer cells downregulated by cyclobenzaprine hydrochloride; B is the screening of the expression of genes downregulated by cyclobenzaprine hydrochloride in esophageal cancer tissues based on the TCGA database; C is the effect of cyclobenzaprine hydrochloride on the protein expression of WDHD1, LIN9, PLOD2, and SLC7A11 in esophageal cancer; D is the effect of cyclobenzaprine hydrochloride on the mRNA expression of WDHD1, LIN9, PLOD2, and SLC7A11 in esophageal cancer.

[0031] Depend on Figure 2 It can be seen that cyclobenzaprine hydrochloride can downregulate the expression of WDHD1 mRNA and protein in esophageal cancer, suggesting that WDHD1 may be a downstream effector molecule of cyclobenzaprine hydrochloride in its anti-esophageal cancer activity. Example 3 Molecular experiment: Possible mechanism of cyclobenzaprine hydrochloride in inhibiting the proliferation and metastasis of esophageal cancer cells

[0032] 1) Transcriptome sequencing experiment: Digest KYSE150 and Eca109 cells in the logarithmic growth phase, count and adjust the cell density to 1×10 7 / mL; take an appropriate amount of cells in logarithmic growth phase and inoculate them in a culture dish with a diameter of 6 cm, and culture them in an incubator at 37°C and 5% CO2; after 24 hours, add 30μM cyclobenzaprine hydrochloride to treat the cells. After 48 hours of treatment, pour out the culture medium, digest the cells moderately with trypsin, collect the cells by centrifugation, and discard the supernatant; wash the cells twice with PBS, aspirate the residual PBS in the centrifuge tube, and add 300μL PBS to resuspend; collect the cells by centrifugation, aspirate the supernatant with a pipette, and then resuspend the cells with 1mL Trizol and send them for transcriptome sequencing;

[0033] 2) PCR experiment: Treat cells according to the method in 1), collect cells, extract RNA, reverse transcribe into cDNA and then perform PCR experiment;

[0034] 3) Western Blot experiment: the steps are the same as in step 2 (3).

[0035] The results are as follows Figure 3 As shown. A is the WDHD1 overexpression efficiency and the effect of cyclobenzaprine hydrochloride on the expression of WDHD1 in KYSE150 and Eca109 cells; B is the effect of cyclobenzaprine hydrochloride combined with WDHD1 on the viability of KYSE150 and Eca109 cells; C is the effect of cyclobenzaprine hydrochloride combined with WDHD1 on the proliferation ability of KYSE150 and Eca109 cells; D is the effect of cyclobenzaprine hydrochloride combined with WDHD1 on the metastatic ability of KYSE150 and Eca109 cells; E is the regulatory effect of cyclobenzaprine hydrochloride on the expression of proteins related to the JAK1 / STAT3 signaling axis.

[0036] Depend on Figure 3 It can be seen that overexpression of WDHD1 can weaken the effects of cyclobenzaprine hydrochloride on the viability, proliferation and metastasis of esophageal cancer cells. In addition, cyclobenzaprine hydrochloride can significantly downregulate the expression levels of JAK1, STAT3, p-JAK1 and p-STAT3 proteins.

[0037] Example 4 Animal experiment: In vivo inhibitory effect of cyclobenzaprine hydrochloride on metastasis of esophageal cancer cells

[0038] Three-week-old male nude mice (weight 18-20 g) were purchased to construct a subcutaneous transplanted tumor model of esophageal cancer in nude mice. The specific steps were as follows: KYSE150 cells in the logarithmic growth phase were digested with 0.25% trypsin solution and the cell density was adjusted to 1×10 7 / mL; 100uL of KYSE150 cell suspension (containing 1×10 6 After injection, the tumor was observed every two days. 3 The nude mice were randomly divided into two groups (the transplanted tumor volumes of the two groups were equivalent). The mouse models were treated with cyclobenzaprine hydrochloride (30 mg / kg) or an equal volume of DMSO intraperitoneally once every two days. The length and width of the transplanted tumor tissue were measured with a vernier caliper, and the tumor volume was calculated using the following formula: Volume (mm 3 ) = length × width 2 / 2. After 10 drug treatments, all nude mice were killed, and the transplanted tumor tissues and important organs such as the heart, liver, lung, and kidney of the mice were dissected out and fixed in 4% paraformaldehyde for preparation into paraffin sections. HE staining was used to evaluate the toxic and side effects of the drugs on important organs, and immunohistochemistry and Western Blot were used to detect the expression of related proteins in tumor tissues.

[0039] The results are as follows Figure 4 As shown. A is the effect of cyclobenzaprine hydrochloride on the growth of tumor tissue in the nude mouse model of esophageal cancer transplanted tumor; B is the change in the volume of tumor tissue in the nude mouse model of esophageal cancer transplanted tumor treated with cyclobenzaprine hydrochloride; C is the change in the weight of tumor tissue in the nude mouse model of esophageal cancer transplanted tumor treated with cyclobenzaprine hydrochloride; D is the immunohistochemical detection of the expression of Ki-67, WDHD1, p-JAK1, p-STAT3 and γ-H2AX in the tumor tissue of the nude mouse model of esophageal cancer transplanted tumor treated with cyclobenzaprine hydrochloride; E is the Western Blot detection of the expression of WDHD1, p-JAK1, p-STAT3 and γ-H2AX in the tumor tissue of the nude mouse model of esophageal cancer transplanted tumor treated with cyclobenzaprine hydrochloride.

[0040] Depend on Figure 4 It can be seen that cyclobenzaprine hydrochloride can significantly reduce the growth ability of esophageal cancer cells in nude mice. At the same time, cyclobenzaprine hydrochloride can significantly downregulate the expression levels of WDHD1, p-JAK1, and p-STAT3 proteins, and upregulate the expression levels of γ-H2AX protein.

[0041] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. Application of cyclobenzaprine hydrochloride in the preparation of drugs for treating esophageal cancer.

2. The use according to claim 1, characterized in that The drug dosage form is tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, electuary preparations, pills, pills, suspensions, wine preparations, tinctures or drops.

3. The use according to claim 1, characterized in that The medicament contains at least one pharmaceutically acceptable carrier or excipient.